Bioxytran is developing a drug to prevent catastrophic brain damage from strokes

BioXyTran Inc. is a biopharmaceutical company founded in 2017 whose mission is to develop anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.
The company focuses on the development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The Company’s lead product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. It will be tested as a potent resuscitative agent to treat Ischemic brain strokes, also known as Cardiac Cerebrovascular Accidents (CVA). In addition, our drug candidate BXT-252, will be tested as a resuscitative agent in a variety of wound healing applications.
BioXyTran Inc. is working hard to develop new molecules that address unmet medical needs. BioXyTran Inc.’s drug candidates have a large market potential as anti-necrotic drugs for multiple disease indications that result from hypoxia.

Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials. Prior to BioXyTran Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 (OTC: BTHE). Between 2001 and 2009, Dr. Platt became a founder of Pro-Pharmaceuticals, Inc. (OTC: PRWP and AMEX: PRW, now NASDAQ: GALT), and served as its chief executive officer and board chairman. In 1995 Dr. Platt founded International Gene Group (NASDAQ: IGGI, GLGS now LPJC); he continued to serve the firm through 2000.

David Platt